arrow
P

Pilar Garrido

Ramón y Cajal University Hospital
H指数:47
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anticoagulation for Cancer Patients in Special Situations: A Narrative Review of Guidelines and Literature

癌症患者特殊情况下抗凝治疗:指南与文献的叙述性综述

Cancers
IF4.4
2026-05-240
OA
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)

驱动基因致癌突变在非小细胞肺癌中的频率及欧洲室内氡暴露的估计(RADON EUROPE研究)

2025-06-260
OA
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer

颅内和系统性进展:在经铂类治疗的表皮生长因子受体外显子20插入突变型晚期非小细胞肺癌中接受阿曼曲单抗治疗

2025-05-100
PRE
Brief Report: Real-World Clinical Utility of Next-Generation Sequencing of Circulating Tumor DNA for Patients With Advanced Lung Squamous Cell Carcinoma (SQUIN)

简报:循环肿瘤DNA下一代测序在晚期肺鳞癌患者中的临床实用性(SQUIN)

2025-02-140
PRE
Nonbacterial Thrombotic Endocarditis (NBTE) Treated With Crizotinib in Lung Adenocarcinoma Harboring ROS-1 Rearrangement: Two Case Report and Review of Literature

非细菌性血栓性心内膜炎(NBTE)在携带ROS-1重排的肺腺癌中用克唑替尼治疗:两例报告及文献综述

2025-02-110
PRE
Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study

早期乳腺癌携带胚系BRCA1/2突变患者中蒽环类药物诱导的心脏毒性:BRCAN研究

2024-11-190
OA
Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology
2024-10-150
OAAI
Influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohort

输注时间对多肿瘤队列免疫治疗效果的影响

2024-09-010
PRE
A spatially informed transcriptomic model to forecast early resistance to front-line osimertinib in advanced EGFRmutant NSCLC

一种基于空间信息的转录组学模型,用于预测晚期EGFRmutant非小细胞肺癌对一线osimertinib的早期耐药性

2024-09-010
PRE
Clinical predictors of long-term responses to immune checkpoint inhibitors (ICI) in a multi-tumor cohort

多肿瘤队列中免疫检查点抑制剂(ICI)长期疗效的临床预测因素

2024-09-010
PRE
Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC)

来自sacituzumab govitecan (SG) 与 docetaxel (doc) 在转移性非小细胞肺癌 (mNSCLC) 中的III期EVOKE-01试验的患者报告结局 (PROs)

2024-09-010
PRE
EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naive to or following prior SRI

EP0031 一种下一代选择性RET抑制剂(SRI):分子应答与临床应答在RET变异阳性实体瘤患者中的相关性研究(该患者群体此前未接受过或曾接受过SRI治疗)

2024-09-010
PRE
Radiotherapy (RT) patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients (pts) with Stage III unresectable non-small cell lung cancer (UR-NSCLC) treated with durvalumab (D) after chemoradiotherapy (CRT)

放射治疗(RT)模式及与PACIFIC-R研究中肺炎相关的因素,该研究是一项真实世界研究,研究对象为接受化疗放疗(CRT)后使用度伐利尤单抗(D)治疗的III期不可切除非小细胞肺癌(UR-NSCLC)患者(pts)。

2024-09-010
PRE
A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)

IO102-IO103疫苗联合帕博利珠单抗的二项期临床试验:完成了一线(1L)治疗晚期头颈鳞状细胞癌(SCCHN)的队列。

2024-09-010
PRE